Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006907/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The aim of the study is to estimate the effect of preoperative gefitinib on the complete
pathological response rate in primary estrogen receptor negative breast cancer at the time of
surgery.
提供机构：
Vivli
创建时间：
2021-04-16
